Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant therapy in melanoma.

P Mohr1, M Weichenthal, A Hauschild

  • 1Department of Dermatology, Elbeklinikum Buxtehude, Germany. p.mohr@elbekliniken.de

Onkologie
|July 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

High-frequency neurostimulation of the right inferior parietal cortex alters the sense of agency: Results from tACS/tRNS and rTMS-EEG studies.

NeuroImage·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.

European psychiatry : the journal of the Association of European Psychiatrists·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Interferon alpha (IFN alpha) is the current standard for adjuvant treatment in high-risk melanoma, improving disease-free survival. Optimal dosage and duration require further study in clinical trials.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Adjuvant therapy for high-risk cutaneous melanoma remains controversial.
  • Previous studies on chemo- and immunotherapy lacked robust prospective validation.
  • Interleukin-2's role and combination therapies require further investigation.

Purpose of the Study:

  • To review the current evidence for adjuvant treatment in high-risk melanoma.
  • To evaluate the efficacy of interferon alpha (IFN alpha) in this setting.
  • To identify areas for future research and clinical trial recommendations.

Main Methods:

  • Review of prospective randomized trials and clinical studies on adjuvant melanoma treatment.
  • Analysis of data on disease-free survival (DFS) and overall survival (OS).

Related Experiment Videos

  • Assessment of interferon alpha (IFN alpha) efficacy at various dosages.

    • Main Results:

    • Interferon alpha (IFN alpha) is the only agent demonstrating reproducible superiority over observation for DFS in high-risk melanoma.
    • Low-dose IFN alpha improves DFS but not overall survival (OS).
    • The benefit of high-dose IFN alpha for OS is still debated; further data on intermediate-dose and modified schedules are pending.

    Conclusions:

    • Interferon alpha (IFN alpha) is the cornerstone of current adjuvant therapy for high-risk melanoma.
    • Optimal dosage and treatment duration for IFN alpha are yet to be determined.
    • High-risk melanoma patients should be enrolled in prospective trials for better treatment recommendations.